Company: LHI
Filing Date: 2025-08-08
Form Type: F-1/A
Source: 0001213900-25-073646
Chunk: 29

Company: Living Homeopathy International Ltd.
Filing Date: 2025-08-08
Form: F-1/A
Chunk 29
---
.235 billion; (ii) the last day of the fiscal year during which the fifth anniversary of the date of this offering occurs; (iii) the date that Living Homeopathy becomes a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, herein referred to as the Exchange Act, which would occur if the market value of Living Homeopathy’s Class A Ordinary Shares that are held by non-affiliates exceeds $700 million as of the last business day of Living Homeopathy’s most recently completed second fiscal quarter; or (iv) the date on which Living Homeopathy has issued more than $1.00 billion in non-convertible debt securities during any three-year period. Upon completion of this offering, Living Homeopathy will report under the Exchange Act as a non-U.S. company with foreign private issuer status. Even after Living Homeopathy no longer qualifies as an emerging growth company, as long as Living Homeopathy qualifies as a foreign private issuer under the Exchange Act it will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:

| ● | the                                                                                             
 sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations 
 in respect of a security registered under the Exchange Act;                                     |

| ● | the                                                                                             
 sections of the Exchange Act requiring insiders to file public reports of their stock ownership 
 and trading activities and liability for insiders who profit from trades made in a short        
 period of time; and                                                                             |

| ● | the                                                                                         
 rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 
 10-Q containing unaudited financial and other specific information, or current reports on   
 Form 8-K, upon the occurrence of specified significant events.                              |

Both foreign private issuers and emerging growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if Living Homeopathy no longer qualifies as an emerging growth company, but remain a foreign private issuer, Living Homeopathy will continue to be exempt from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer.

<div align='center'>12</div>

Implications of Being a Foreign Private Issuer Living Homeopathy is incorporated in the Cayman Islands and more than 50% of its outstanding voting securities are not directly or indirectly held by residents of the United States. Therefore, Living Homeopathy is a “foreign private issuer,” as